Recombinant factor VIIa as last‐resort treatment of desperate haemorrhage
Studies are inconclusive regarding clinical outcomes after administration of recombinant activated coagulation factor VII (rFVIIa) during severe
haemorrhage. The circumstances encountered during desperate haemorrhage make it difficult to include the most critically ill patients that could possibly benefit the most from such treatment into randomized controlled trials. We report our experience with rFVIIa as last‐resort
treatment of desperate haemorrhage when all standard treatment has failed. Materials and Methods
Hospital charts of all consecutive patients treated with rFVIIa for
desperate non‐haemophilic bleeding over a 10‐year period at the single institution administering rFVIIa were surveyed for treatment indications, clinical outcome, transfusion need and coagulation profiles.
Fifty‐five rFVIIa treatment occasions of desperate bleeding were identified in 54 patients (median age 54 years). A single rFVIIa dose was used in 86%, and haemorrhage was considered effectively
contained by immediate clinical response on 81% of occasions. Overall, 38 patients (71%) survived for over 30 days. Two thromboembolic events occurred (3.6%). The 24‐h mortality in 45 rFVIIa immediate clinical responders and 10 non‐responders was 2% and 50%,
respectively (P = 0.0004), and the 30‐day mortality was 25% and 60%, respectively (P = 0.05). Blood product use decreased with rFVIIa (P < 0.01)
as did the prothrombin time (20.0‐13.3 s, P < 0.0001). Conclusions
The majority of unselected consecutive patients receiving
rFVIIa as last‐resort treatment for desperate haemorrhage were considered to have immediate clinical response as well as reduced transfusion requirements and correction of coagulation parameters. An immediate clinical response to rFVIIa may
possibly be predictive of survival.